News & Updates

NAFLD does not raise severe COVID-19 risk

11 Feb 2022

There is no causal relationship between genetic predisposition to nonalcoholic fatty liver disease (NAFLD) and increased risk of developing severe COVID-19, according to a Mendelian randomization study.

NAFLD does not raise severe COVID-19 risk

11 Feb 2022

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

06 Feb 2022

The chances of hepatitis B surface antigen (HBsAg) loss after withdrawing nucleo(s)tide analogue (NUC) treatment depend on factors such as patient ethnicity, end-of-treatment antigen levels, and HBV genotype, a new study reports.

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

06 Feb 2022

Hepatitis E virus resistant to alcohol-based disinfectants

06 Feb 2022

Alcohol-based hand disinfectants might be insufficient to suppress hepatitis E virus infectivity, a new study has found.

Hepatitis E virus resistant to alcohol-based disinfectants

06 Feb 2022

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

27 Jan 2022

In patients with advanced chronic liver disease (ACLD), ratio of procoagulant factor VIII to anticoagulant protein C (FVIII/PC) is significantly prognostic of decompensation, death, and acute-on-chronic liver failure (ACLF), a new study has found. However, FVIII/PC is not related to thrombosis and does not reflect coagulation.

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

27 Jan 2022

$Tailor refractory ascites treatment according to patient context, study says$

Tailor refractory ascites treatment according to patient context, study says

23 Jan 2022

Refractory ascites is a severe complication of liver cirrhosis leading to poor prognosis and is curable only through liver transplantation, reports a recent meta-analysis.

Tailor refractory ascites treatment according to patient context, study says

23 Jan 2022

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Among patients with nonalcoholic fatty liver disease (NAFLD), the more severe the liver fibrosis, the higher the risk of developing extrahepatic events, a study has found. Specifically, the risk is low among patients with mild fibrosis, low but clinically relevant among those with moderate fibrosis, and high among those with severe to advanced fibrosis.

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

21 Jan 2022

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

17 Jan 2022

The visceral fat area (VFA) index and visceral fat density (VFD) are independently related to the prevalence of nonalcoholic fatty liver disease (NAFLD), according to a study. However, the VFD appears to have a stronger link to the incidence of NAFLD than the VFA index.

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

17 Jan 2022

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022 by

For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

13 Jan 2022

Autoimmune hepatitis ups 10-year risk of cancer

12 Jan 2022

Autoimmune hepatitis (AIH), a chronic inflammatory liver disease, appears to increase the 10-year risk of cancer by 1.5-fold relative to age- and sex-matched controls, a study has shown.

Autoimmune hepatitis ups 10-year risk of cancer

12 Jan 2022

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022 by

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

06 Jan 2022

News & Updates

Filter by Specialty:

Specialty:

NAFLD does not raise severe COVID-19 risk

NAFLD does not raise severe COVID-19 risk

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal

Hepatitis E virus resistant to alcohol-based disinfectants

Hepatitis E virus resistant to alcohol-based disinfectants

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

FVIII/PC predicts complication risk in ACLD, but not coagulation potential

Tailor refractory ascites treatment according to patient context, study says

Tailor refractory ascites treatment according to patient context, study says

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

Risk of extrahepatic events high among NAFLD patients with severe liver scarring

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

Visceral fat density shows stronger association with NAFLD incidence than visceral fat area

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor

Autoimmune hepatitis ups 10-year risk of cancer

Autoimmune hepatitis ups 10-year risk of cancer

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC